ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,970.84
-1.11%
US Tech 100
20,897.20
-1.35%
다우존스 지수
42,992.21
-0.77%
Bitcoin
94,359.12
0.21%
Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Halozyme Therapeutics Incorporated (HALO)

  7. Halozyme Therapeutics Incorporated (HALO) 뉴스

HALO

Halozyme Therapeutics (HALO)

Halozyme Therapeutics Incorporated
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:HALO
일자시간출처헤드라인심볼기업
2024/12/0406:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
2024/12/0406:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
2024/11/2722:30PR Newswire (US)Halozyme to Present at Upcoming Investor ConferencesNASDAQ:HALOHalozyme Therapeutics Incorporated
2024/11/2222:35PR Newswire (US)Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in DiscussionsNASDAQ:HALOHalozyme Therapeutics Incorporated
2024/11/1506:15PR Newswire (US)Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash TransactionNASDAQ:HALOHalozyme Therapeutics Incorporated
2024/11/1223:36Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:HALOHalozyme Therapeutics Incorporated
2024/11/0105:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HALOHalozyme Therapeutics Incorporated
2024/11/0105:01PR Newswire (US)HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTSNASDAQ:HALOHalozyme Therapeutics Incorporated
2024/10/2419:30PR Newswire (US)HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPENASDAQ:HALOHalozyme Therapeutics Incorporated
2024/10/2405:30PR Newswire (US)Halozyme to Report Third Quarter 2024 Financial and Operating ResultsNASDAQ:HALOHalozyme Therapeutics Incorporated
2024/10/1707:53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
2024/10/1705:14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
2024/10/1605:34Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
2024/10/1021:09InvestorsHub NewsWireZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor UseNASDAQ:HALOHalozyme Therapeutics Incorporated
2024/10/1006:39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
2024/10/1005:09Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
2024/10/0905:08Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
2024/10/0321:00PR Newswire (US)Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx for ENHANZE®NASDAQ:HALOHalozyme Therapeutics Incorporated
2024/09/2707:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
2024/09/2705:05Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
2024/09/2605:00Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
2024/09/2505:05Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
2024/09/1907:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
2024/09/1905:01Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
2024/09/1805:03Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
2024/09/1402:30PR Newswire (US)Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple SclerosisNASDAQ:HALOHalozyme Therapeutics Incorporated
2024/09/1309:00PR Newswire (US)Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of CancerNASDAQ:HALOHalozyme Therapeutics Incorporated
2024/09/1306:56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
2024/09/1305:12Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
2024/09/1205:05Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:HALOHalozyme Therapeutics Incorporated
 검색 관련기사 보기:NASDAQ:HALO

최근 히스토리

USI
USTECH100
US Tech 100
FX
USDJPY
US Dollar vs Yen
NYSE
AXP
American Express
CCOM
US500
US 500
COIN
XRPUSD
Ripple
NYSE
BAC
Bank of America
CCOM
US30
US 30
NYSE
DIS
Walt Disney
USOTC
BNPQY
BNP Paribas (QX)
NYSE
KO
Coca Cola
PM
XAUUSD
Gold vs US Dollar
SPI
SP500
S&P 500
USOTC
BASFY
BASF (QX)
AMEX
XLE
Energy Select Sector SPDR
NYSE
JPM
JP Morgan Chase
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유